Quick Answer
Aurinia Pharmaceuticals Inc. reported Total Assets of $751.59 million for the year ending 2025.
- Aurinia Pharmaceuticals Inc. showed an increase of +36.5% in Total Assets from 2024 to 2025.
- This data is from Aurinia Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $417.08 million | Q2 2021: $386.27 million | Q3 2021: $360.07 million | Q1 2022: $506.90 million | Q2 2022: $482.15 million | Q3 2022: $488.29 million | Q1 2023: $451.76 million | Q2 2023: $548.90 million | Q3 2023: $555.01 million | Q1 2024: $516.63 million | Q2 2024: $523.53 million | Q3 2024: $549.36 million | Q1 2025: $504.85 million | Q2 2025: $502.56 million | Q3 2025: $527.53 million.
- Over the full 7 years of available data (2019 to 2025), Aurinia Pharmaceuticals Inc.'s Total Assets has grown by 131.8%.
- Historical annual values: Fiscal year 2025: $751.59 million | Fiscal year 2024: $550.65 million | Fiscal year 2023: $548.06 million | Fiscal year 2022: $470.86 million | Fiscal year 2021: $543.37 million | Fiscal year 2020: $463.66 million | Fiscal year 2019: $324.30 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: